Tag: in vivo CRISPR candidate

  • Why Intellia Therapeutics is Up $4 Today

    Why Intellia Therapeutics is Up $4 Today

    Keep an eye on Intellia Therapeutics (NTLA).   Tomorrow, the company will present interim clinical data from its ongoing first-in-human studies of NTLA-2002 and NTLA-2001 for the treatment of hereditary angioedema (HAE). According to the National Association for Rare Disorders, “Hereditary angioedema is a rare inherited disorder characterized by recurrent episodes of the accumulation of fluids…